XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Outlines 2021 Business Strategies for COVID-19 PCR Testing and Psychedelic Treatments
XPhyto Therapeutics Corp. plans to commercialize its rapid and portable PCR Kit this year to provide point-of-care diagnosticsThe company is confident about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021Hugh Rogers, CEO and Director of XPhyto, revealed in the latest news release that the company will make investments and development of psychedelic treatments XPhyto Therapeutics Corp. (CSE: XPHY)…